Isotretinoin prescribing: Finding a balance between benefit and risk

Pharmacoepidemiology and Drug Safety

Volumn 14, Issue 9, 2005, Pages 611-613

  Stern, Robert S ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOTRETINOIN;

ACNE; CONTRACEPTION; DEPRESSION; DRUG EXPOSURE; DRUG LABELING; EDITORIAL; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; MARKETING; PREGNANCY TEST; PRESCRIPTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SUICIDE; TERATOGENICITY; UNITED STATES;

ACNE VULGARIS; ADULT; FEMALE; GUIDELINES; HUMANS; ISOTRETINOIN; KERATOLYTIC AGENTS; PREGNANCY; PRESCRIPTIONS, DRUG; RISK ASSESSMENT; TERATOGENS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 25444441206     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.1145     Document Type: Editorial

References (15)

1. Peck GL, Olsen TG, Yoder FW et al. Prolonged remissions of cystic and conglobate acne with 13-cis-retinoic acid. N Engl J Med 1979; 300: 329-333.
2. Stem RS, Rosa F, Baum C. Isotretinoin and pregnancy. J Am Acad Dermatol 1984; 10: 851-854.
3. Kolata G. Anti-acne drug faulted in birth defects. N Y Times 1988; 1.
4. Graham DJ, Rosa F, Baum C. Maternal exposure to accutane. Position paper 1998; 39.
5. Department of Health and Human Services. Food and Drug Administration Center for Drug Evaluation and Research. 1998; NDA 18-662.
6. Mendelsohn AB, Governale L, Trontell A, Seligman P. Changes in isotretinoin prescribing before and after implementation of the System to Manage Accutane Related Teratogenicitytrade mark (SMARTtrade mark) risk management program. Pharmacoepidemiol Drug Safe 2005; 14: 615-618.
7. Stern RS. Medication and medical service utilization for acne 1995-1998. J Am Acad Dermatol 2000; 43: 1042-1048.
8. Jick SS, Kremers HM, Vasilakis-Scaramozza C. Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide. Arch Dermatol 2000; 136: 1231-1236.
9. Chia CY, Lane W, Chibnall J, Allen A, Siegfried E. Isotretinoin therapy and mood changes in adolescents with moderate to severe acne: a cohort study. Arch Dermatol 2005; 141: 557-560.
10. Brinker A, Kornegay C, Nourjah P. Trends in adherence to a revised risk management program designed to decrease or eliminate isotretinoin-exposed pregnancies: evaluation of the accutane SMART program. Arch Dermatol 2005; 141: 563-569.
11. Mitchell AA, Van Bennekom CM, Louik C. A pregnancy-prevention program in women of childbearing age receiving isotretinoin. N Engl J Med 1995; 333: 101-106.
12. Stern RS. The prevalence of acne on the basis of physical examination. J Am Acad Dermatol 1992; 26: 931-935.
13. Zeldis JB, Williams BA, Thomas SD, Elsayed ME. S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide. Clin Ther 1999; 21: 319-330.
14. Stern RS. When a uniquely effective drug is teratogenic. The case of isotretinoin. N Engl J Med 1989; 320: 1007-1009.
15. Testimony of David J. Graham, MD, MPH, November 18, 2004 to US Congressional Committee. 2004; 1-6.